Mr. Sebastien Plouffe reports

DEFENCE THERAPEUTICS APPOINTS FINANCE EXECUTIVE SHERRY AULIN TO ITS BOARD OF DIRECTORS

Defence Therapeutics Inc. has appointed Sherry Aulin to its board of directors. Ms. Aulin will also serve as a member of the company's audit committee.

Sherry Aulin is a finance executive with more than 20 years of experience working with public companies and in the capital markets. She was most recently chief financial officer of Xenon Pharmaceuticals, a neuroscience-focused biopharmaceutical company, where she served for over a decade. During her tenure, she played a key role in the company's Nasdaq IPO (initial public offering), was instrumental in shaping corporate strategy and led the company's financing activities, raising more than $1-billion (U.S.) in equity capital.

Earlier in her career, Ms. Aulin held senior roles at KPMG LLP, where she provided professional services to publicly traded companies across a range of industries, including life sciences. She brings extensive experience in corporate finance, capital markets, strategic planning, investor relations and public-company operations. Ms. Aulin holds a bachelor of commerce from the University of British Columbia and is a chartered professional accountant and chartered accountant. She currently serves on the board of directors of Life Sciences British Columbia and is a past recipient of Business in Vancouver's Forty Under 40 award.

"I am pleased to join Defence Therapeutics' board of directors at such an exciting time for the company," said Ms. Aulin. "Defence's innovative technology platform has the potential to create meaningful opportunities in the development of next-generation therapeutics. I look forward to bringing my expertise in the capital markets and public-company leadership to the board and supporting management in strategically advancing its programs and creating long-term value for shareholders."

"Sherry is an exceptional addition to Defence's board of directors, and I am pleased to welcome her," said Sebastien Plouffe, Defence Therapeutics' executive chairman. "Her significant experience with public companies and in the capital markets, combined with her deep understanding of the biotechnology sector, brings a level of expertise that is highly valuable to Defence at this important inflection point for the company. Sherry played a pivotal role in the evolution of Xenon Pharmaceuticals, from its initial public offering through more than a decade of corporate development, strategic planning and capital formation. That experience gives her a first-hand perspective on what it takes to build a successful public biotechnology company and I look forward to her valued contributions."

Pursuant to the appointment of Ms. Aulin as director, the company has granted 400,000 incentive stock options to Ms. Aulin exercisable at a price of 40 cents per share for a period of five years, in accordance with the terms and conditions of Defence's omnibus incentive plan. Of these options, 200,000 are vested immediately and 200,000 will be vested on the first anniversary of the date of grant.

About Defence Therapeutics Inc.

Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum precision drug delivery platform, Defence is working to enhance the potency of ADCs (antibody-drug conjugates) and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursuing cutting-edge science and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most.

We seek Safe Harbor.